Holen Sie sich die Stockscreener-App
5.12
0.39%
-0.02
Handel nachbörslich:
5.09
-0.03
-0.59%
Schlusskurs vom Vortag:
$5.14
Offen:
$5.11
24-Stunden-Volumen:
1.42M
Relative Volume:
0.67
Marktkapitalisierung:
$800.69M
Einnahmen:
$181.41M
Nettoeinkommen (Verlust:
$-59.56M
KGV:
-12.19
EPS:
-0.42
Netto-Cashflow:
$-38.83M
1W Leistung:
-3.21%
1M Leistung:
+13.53%
6M Leistung:
+55.62%
1J Leistung:
+108.98%
1-Tages-Spanne:
$5.085
$5.235
1-Wochen-Bereich:
$5.05
$5.40
52-Wochen-Spanne:
$2.095
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Vergleichen Sie XERS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.12 | 847.22M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
What analysts say about Xeris Biopharma Holdings Inc. stockAccelerated capital growth - jammulinksnews.com
Is Xeris Biopharma Holdings Inc. a good long term investmentFree Technical Analysis Support - jammulinksnews.com
How Xeris Biopharma Holdings Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
Xponance Inc. Invests $57,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc. Stock Analysis and ForecastRapidly growing investment returns - jammulinksnews.com
What drives Xeris Biopharma Holdings Inc. stock priceBreakout stock performance - Autocar Professional
how xeris biopharma holdings inc. stock performs during market volatilityMarket Timing Advice - Newser
why xeris biopharma holdings inc. stock attracts strong analyst attentionMassive Upside Selection - Newser
Brown Advisory Inc. Has $630,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Why Xeris Biopharma Holdings Inc. stock attracts strong analyst attentionProfessional Stock Screener - Newser
What makes Xeris Biopharma Holdings Inc. stock price move sharplyBreakout Momentum Stocks - Newser
A Piece Of The Puzzle Missing From Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) 25% Share Price Climb - simplywall.st
Xeris Biopharma's 7% Spike: Unraveling the Mysterious Move - AInvest
Wealth Enhancement Advisory Services LLC Has $172,000 Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma's 10% Spike: A Technical and Market Flow Deep Dive - AInvest
Xeris Biopharma (NASDAQ:XERS) versus Mangoceuticals (NASDAQ:MGRX) Head to Head Review - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rhumbline Advisers Increases Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Wealth Enhancement Advisory Services LLC Raises Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing - Seeking Alpha
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity - Defense World
Pallas Capital Advisors LLC Acquires New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Squarepoint Ops LLC Has $138,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Two Sigma Advisers LP Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings - Defense World
Leerink Partnrs Forecasts Lower Earnings for Xeris Biopharma - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 5.5%Should You Sell? - MarketBeat
Leerink Partners raises Xeris Pharmaceuticals stock price target By Investing.com - Investing.com UK
Transcript : Xeris Biopharma Holdings, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 01 - MarketScreener
Xeris at Jefferies Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
xeris biopharma holds annual meeting, elects directors By Investing.com - Investing.com South Africa
xeris biopharma holds annual meeting, elects directors - Investing.com
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug - Crain's Chicago Business
Xeris Biopharma projects $1 billion Recorlev revenue by 2035 - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Rings the Closing Bell - Nasdaq
Transcript : Xeris Biopharma Holdings, Inc.Analyst/Investor Day - marketscreener.com
Xeris Biopharma Holdings, Inc. Reaffirms Revenue Guidance for the Year 2025 - marketscreener.com
Xeris Biopharma Holdings Shares Fall; 2025 Revenue Guidance Reaffirmed, Long-Term Outlook Set - marketscreener.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day - mx.advfn.com
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):